---
title: "MediciNova says SEANOBI-ALS expanded-access study of MN-166 reaches 200-patient enrollment target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292763424.md"
description: "MediciNova announced that its NIH-funded SEANOBI-ALS expanded-access study of MN-166 (ibudilast) has reached its target enrollment of 200 patients. The program provides the drug to ALS patients ineligible for randomized clinical trials under the ACT for ALS initiative. Final patient follow-ups are expected to conclude in early 2027, with subsequent data analysis planned for scientific presentations and peer-reviewed publications."
datetime: "2026-07-15T12:03:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292763424.md)
  - [en](https://longbridge.com/en/news/292763424.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292763424.md)
---

# MediciNova says SEANOBI-ALS expanded-access study of MN-166 reaches 200-patient enrollment target

-   MediciNova reached its 200-patient target enrollment in the NIH-funded SEANOBI-ALS expanded-access study of MN-166 (ibudilast) in ALS. \* Program supplies MN-166 to ALS patients ineligible for ongoing randomized clinical trials under the ACT for ALS initiative. \* Final patient follow-ups are projected to end in early 2027, with data analysis planned to support scientific presentations and peer-reviewed publications. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150800PRIMZONEFULLFEED9761981) on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [MNOV.US](https://longbridge.com/en/quote/MNOV.US.md)
- [4875.JP](https://longbridge.com/en/quote/4875.JP.md)

## Related News & Research

- [MediciNova says US patent office allows ibudilast–anti-PD-1 combo claims for glioblastoma treatment](https://longbridge.com/en/news/291279545.md)
- [12:22 ETEmpo Health® Announces Peer-Reviewed Publication, APMA Seal of Approval, and SOC 2 Type 2 Compliance](https://longbridge.com/en/news/294393288.md)
- [Burelle announces availability of 2026 half-year financial report](https://longbridge.com/en/news/293960435.md)
- [Stempoint Capital LP Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/294341144.md)
- [X4 Pharmaceuticals (XFOR) to Release Quarterly Earnings on Thursday](https://longbridge.com/en/news/294330509.md)